ERBB2 and cancer: Currently, there are DC vaccine strategies employed for clinical trials incorporating priming from HER2, MUC1, autologous cancer cells, and personalized neoantigens, many of which have proven to be safe and effective (see Table 2) [81,82,91,92,93].